2024 - 2032 年前列腺癌診斷市場機會、成長動力、產業趨勢分析與預測

Prostate Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月01日 | 出版商:

Global Market Insights Inc. | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球前列腺癌診斷市場估值為45億美元，預計2024年至2032年複合年成長率為10.5%。推動的，以及對創新診斷方法的重大投資。這些綜合因素正在推動市場向前發展。隨著前列腺癌變得越來越普遍，特別是在老齡化人群中，對及時、準確的診斷工具的需求日益成長。公共衛生運動和宣傳工作鼓勵男性定期接受檢查，進一步推動市場需求。

此外，對早期檢測和個人化治療方案的關注正在促進先進診斷技術的採用。市場按測試類型分為診斷測試和影像測試，其中診斷測試處於領先地位。 2023 年，診斷測試產生了 29 億美元的收入，這主要歸功於其在早期檢測中的關鍵作用。 PSA（前列腺特異性抗原）測試尤其重要，因為它可以測量血液中這種與癌症相關的蛋白質的水平。

PSA 檢測通常用於常規健康檢查，特別是對於 50 歲以上的男性，隨著檢測靈敏度的提高，這些診斷方法將繼續在癌症檢測中發揮至關重要的作用。就癌症類型而言，前列腺癌佔前列腺癌病例的 95% 以上，2023 年產生的收入最高，為 41 億美元。這種影響前列腺細胞的癌症是最常見的，推動了對專業診斷工具的需求。北美市場 2023 年營收為 18 億美元，預計到 2032 年將以 9.9% 的複合年成長率大幅成長。此外，FDA 等監管機構支持快速採用創新診斷解決方案，包括液體活體組織切片和基因檢測，進一步增強市場的成長潛力。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	45 億美元
預測值	111 億美元
複合年成長率	10.5%

產業生態系統分析
產業影響力
- 成長動力
  - 攝護腺癌盛行率增加
  - 技術進步
  - 提高意識和篩檢舉措
  - 攝護腺癌診斷測試日益普及
- 產業陷阱與挑戰
  - 缺乏熟練的專業人員
  - 嚴格規定
成長潛力分析
技術景觀
監管環境
報銷場景
主要市場趨勢
波特的分析
PESTEL分析
差距分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按測試類型，2021 - 2032 年

主要趨勢
診斷測試
- PSA
- 攝護腺切片
- 分子/基因組測試
- 其他診斷測試
影像學檢查
- 經直腸超音波 (TRUS)
- 核磁共振成像
- CT掃描
- 其他影像學檢查

第 6 章：市場估計與預測：按癌症類型，2021 - 2032 年

主要趨勢
攝護腺腺癌
小細胞癌
其他前列腺癌類型

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
診斷實驗室
癌症研究機構
其他最終用途

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 波蘭
- 瑞典
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 印尼
- 菲律賓
- 越南
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 哥倫比亞
- 智利
- 秘魯
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 土耳其
- 伊朗
- 以色列
- 中東和非洲其他地區

第 9 章：公司簡介

Abbott Laboratories
AdvaCare Pharma
Beckman Coulter, Inc. (Danaher Corporation)
Becton, Dickinson and Company
BIOMERIEUX
F. Hoffmann-La Roche Ltd.
FUJIFILM Holdings Corporation
GE Healthcare Technologies Inc.
Glycanostcs Ltd.
Healgen
KOELIS
Koninklijke Philips NV
Metamark Genetics, Inc.
miR Scientific
Myriad Genetics, Inc.
Proteomedix
Siemens Healthineers AG
Veracyte

簡介目錄

Product Code: 6107

The Global Prostate Cancer Diagnostics Market was valued at USD 4.5 billion in 2023 and is projected to grow at a CAGR of 10.5% from 2024 to 2032. This expansion is driven by the rising incidence of prostate cancer, increasing awareness about risk factors, technological advancements, and significant investments in innovative diagnostic methods. These combined factors are pushing the market forward. As prostate cancer becomes more prevalent, especially among aging populations, there is a growing need for timely and accurate diagnostic tools. Public health campaigns and awareness efforts encourage men to undergo regular screenings, further propelling market demand.

Additionally, the focus on early detection and personalized treatment options is boosting the adoption of advanced diagnostic technologies. The market is segmented by test type into diagnostic tests and imaging tests, with diagnostic tests leading the way. In 2023, diagnostic tests generated USD 2.9 billion in revenue, largely due to their critical role in early detection. The PSA (prostate-specific antigen) test is particularly crucial, as it measures the level of this cancer-related protein in the blood.

PSA testing is commonly used in routine health checks, particularly for men over 50, and with advancements in testing sensitivity, these diagnostics continue to play a vital role in cancer detection. In terms of cancer types, the prostatic adenocarcinoma, which accounts for over 95% of prostate cancer cases, generated the highest revenue at USD 4.1 billion in 2023. This type of cancer, affecting the gland cells of the prostate, is the most prevalent, driving the need for specialized diagnostic tools. The North America market, which accounted for USD 1.8 billion in revenue in 2023, is anticipated to grow significantly at a CAGR of 9.9% through 2032. This growth is fueled by a combination of high awareness levels, advanced healthcare infrastructure, and regular screening programs. Additionally, regulatory bodies such as the FDA support the rapid adoption of innovative diagnostic solutions, including liquid biopsy and genetic testing, further enhancing the market's growth potential.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$4.5 Billion
Forecast Value	$11.1 Billion
CAGR	10.5%

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of prostate cancer
  - 3.2.1.2 Technological advancement
  - 3.2.1.3 Surging awareness and screening initiatives
  - 3.2.1.4 Increasing popularity of prostate cancer diagnostic tests
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Lack of skilled professionals
  - 3.2.2.2 Stringent regulations
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Reimbursement scenario
3.7 Key market trends
3.8 Porter's analysis
3.9 PESTEL analysis
3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Diagnostics tests
- 5.2.1 PSA
- 5.2.2 Prostate biopsy
- 5.2.3 Molecular/ genomic test
- 5.2.4 Other diagnostics tests
5.3 Imaging tests
- 5.3.1 Transrectal ultrasound (TRUS)
- 5.3.2 MRI
- 5.3.3 CT Scan
- 5.3.4 Other imaging tests

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Prostatic adenocarcinoma
6.3 Small cell carcinoma
6.4 Other prostate cancer types

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Diagnostic laboratories
7.4 Cancer research institutes
7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Poland
- 8.3.7 Sweden
- 8.3.8 Netherlands
- 8.3.9 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Indonesia
- 8.4.7 Philippines
- 8.4.8 Vietnam
- 8.4.9 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Colombia
- 8.5.5 Chile
- 8.5.6 Peru
- 8.5.7 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Turkey
- 8.6.5 Iran
- 8.6.6 Israel
- 8.6.7 Rest of Middle East and Africa